FAQs: Improving Empiric Antibiotic Regimens for HABP/VABP in the ICU

In this episode, Marion Elligsen, BScPhm, MSc, RPh, ACPR; Keith S Kaye, MD, MPH; and Andrew Shorr, MD, MPH, MBA, discuss key considerations for selecting empiric antibiotic regimens in patients with HABP/VABP in the intensive care unit, including: 

• The role of novel β-lactam/β-lactamase inhibitor combinations
• Use of clinical predictions scores (eg, Drug Resistance in Pneumonia [DRIP] score) to predict risk for pneumonia caused by multidrug-resistant pathogens
• Application of rapid diagnostic testing in critically ill patients with pneumonia, including current limitations
• Implementation of advanced antibiograms and clinical prediction scores
• Clinical utility of biomarkers for pneumonia (eg, procalcitonin)
• Application of updated nosocomial pneumonia classifications in clinical practice

Faculty:
Marion Elligsen, BScPhm, ​ MSc, RPh, ACPR​
Practice-Based Researcher​
Sunnybrook Research Institute​
Antimicrobial Stewardship Pharmacy Lead​
Department of Pharmacy​
Sunnybrook Health Sciences Centre​
Toronto, Ontario, Canada​

Keith S. Kaye, MD, MPH
Chief  
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Andrew Shorr, MD, MPH, MBA​
Director​
Pulmonary and Critical Care Medicine​
Medstar Washington Hospital Center​
Washington, DC​

Content based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp. 

Link to full program:
https://bit.ly/3HaZpYw

Link to downloadable slideset:
https://bit.ly/3UxHoqr

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.